Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Vertex (VRTX) PT Raised to $459 at Morgan Stanley
February 11, 2025 7:10 AM ESTMorgan Stanley analyst Terence Flynn raised the price target on Vertex (NASDAQ: VRTX) to $459.00 (from $450.00) while maintaining a Equalweight rating.
The analyst comments "VRTX posted a 4Q beat and first time 2025 Rev/expense guidance bracketed consensus. Looking ahead the focus is on... More
Vertex Pharma (VRTX) Misses Q4 EPS by 4c, Revenues Beat
February 10, 2025 4:04 PM ESTVertex Pharma (NASDAQ: VRTX) reported Q4 EPS of $3.98, $0.04 worse than the analyst estimate of $4.02. Revenue for the quarter came in at $2.91 billion versus the consensus estimate of $2.79 billion.
GUIDANCE:
Vertex Pharma sees FY2025 revenue of $11.75-12 billion, versus the consensus of... More
